Mirum Pharmaceuticals (NASDAQ:MIRM) has received mixed analyst ratings over the past three months, with 12 analysts offering a range of bullish to bearish perspectives. The average 12-month price target is $58.5, with a high of $77.00 and a low of $37.00. However, there has been a 17.89% decrease in the average price target, indicating a negative shift in sentiment. Analysts from firms like JMP Securities, Raymond James, HC Wainwright & Co., Cantor Fitzgerald, JP Morgan, Morgan Stanley, and Evercore ISI Group have provided various ratings and price target adjustments. Mirum Pharmaceuticals is a biopharmaceutical company with a focus on rare and orphan diseases, and its product Livmarli is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). The company has shown a revenue growth rate of 154.13% as of September 30, 2023, but faces challenges with a net margin of -49.42% and a debt-to-equity ratio of 1.14.